Kailera Therapeutics (NASDAQ:KLRA) Reaches New 12-Month Low – Time to Sell?

Kailera Therapeutics, Inc. (NASDAQ:KLRA) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $18.39 and last traded at $18.41, with a volume of 45587 shares traded. The stock had previously closed at $19.30.

Analysts Set New Price Targets

Several brokerages have issued reports on KLRA. Zacks Research raised shares of Kailera Therapeutics to a “hold” rating in a research report on Wednesday, May 13th. TD Cowen started coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They issued a “buy” rating and a $57.00 price objective for the company. Leerink Partners assumed coverage on shares of Kailera Therapeutics in a research note on Tuesday, May 12th. They set an “outperform” rating and a $36.00 target price for the company. Evercore initiated coverage on Kailera Therapeutics in a report on Tuesday, May 12th. They set an “outperform” rating for the company. Finally, Wall Street Zen cut shares of Kailera Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, May 30th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and an average price target of $42.75.

Kailera Therapeutics Stock Up 1.3%

The firm has a market capitalization of $2.40 billion and a price-to-earnings ratio of -0.01. The business’s 50 day moving average is $20.87.

Kailera Therapeutics (NASDAQ:KLRA) last issued its earnings results on Tuesday, May 26th. The company reported ($3,650.00) earnings per share (EPS) for the quarter.

Insider Buying and Selling

In other news, major shareholder Rtw Investments, Lp acquired 500,000 shares of the firm’s stock in a transaction that occurred on Monday, April 20th. The stock was purchased at an average price of $16.00 per share, with a total value of $8,000,000.00. Following the purchase, the insider owned 10,776,820 shares of the company’s stock, valued at approximately $172,429,120. This trade represents a 4.87% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Andrew T. Kaplan purchased 8,398,438 shares of the stock in a transaction dated Monday, April 20th. The shares were acquired at an average price of $16.00 per share, for a total transaction of $134,375,008.00. Following the acquisition, the director directly owned 26,255,581 shares of the company’s stock, valued at $420,089,296. This represents a 47.03% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last 90 days, insiders bought 10,460,938 shares of company stock valued at $167,375,008.

Kailera Therapeutics Company Profile

We are an advanced clinical-stage biotechnology company focused on elevating the next era of obesity care by advancing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. Obesity is a chronic, progressive and debilitating disease that impacts over 1 billion people globally and requires long-term comprehensive treatment. Since obesity is the driving factor for more than 200 comorbidities and represents a significant contributor to increased morbidity and mortality, our vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives.